NASDAQ:LYEL Lyell Immunopharma (LYEL) Stock Price, News & Analysis $1.64 +0.01 (+0.61%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.61▼$1.7250-Day Range$1.31▼$2.7752-Week Range$1.18▼$3.26Volume372,722 shsAverage Volume987,653 shsMarket Capitalization$418.10 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Lyell Immunopharma alerts: Email Address Lyell Immunopharma MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside143.9% Upside$4.00 Price TargetShort InterestBearish13.59% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.85) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.43 out of 5 starsMedical Sector547th out of 936 stocksPharmaceutical Preparations Industry247th out of 436 stocks 3.2 Analyst's Opinion Consensus RatingLyell Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageLyell Immunopharma has only been the subject of 2 research reports in the past 90 days.Read more about Lyell Immunopharma's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.59% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Lyell Immunopharma has recently decreased by 9.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LYEL. Previous Next 2.7 News and Social Media Coverage News SentimentLyell Immunopharma has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Lyell Immunopharma this week, compared to 1 article on an average week.Search Interest3 people have searched for LYEL on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders25.10% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyell Immunopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lyell Immunopharma are expected to decrease in the coming year, from ($0.85) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lyell Immunopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.Let me explain in this new documentary video About Lyell Immunopharma Stock (NASDAQ:LYEL)Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Read More LYEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LYEL Stock News HeadlinesJune 26, 2024 | globenewswire.comLyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion TechnologyJune 3, 2024 | globenewswire.comLyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 13, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on Lyell Immunopharma (LYEL)May 7, 2024 | globenewswire.comLyell Immunopharma to Participate in BofA Securities Health Care ConferenceMay 7, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Crispr Therapeutics AG (CRSP)May 7, 2024 | finance.yahoo.comLyell Immunopharma First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)May 6, 2024 | investorplace.comLYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q1 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 6, 2024 | globenewswire.comLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024April 16, 2024 | morningstar.comLyell Immunopharma Inc Ordinary Shares LYELApril 12, 2024 | benzinga.comArgan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On FridayApril 4, 2024 | finance.yahoo.comOutpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual MeetingApril 2, 2024 | seekingalpha.comBiomea Fusion drops as JPMorgan downgrades on data for lead assetMarch 20, 2024 | finance.yahoo.com2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsMarch 17, 2024 | finance.yahoo.comLyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returnsMarch 10, 2024 | finanznachrichten.deLyell Immunopharma, Inc: Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual MeetingMarch 5, 2024 | globenewswire.comLyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual MeetingSee More Headlines Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LYEL CUSIPN/A CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees224Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$6.00 Low Stock Price Target$1.00 Potential Upside/Downside+143.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-234,630,000.00 Net Margins-335,794.09% Pretax Margin-335,794.12% Return on Equity-33.92% Return on Assets-29.71% Debt Debt-to-Equity RatioN/A Current Ratio16.51 Quick Ratio16.51 Sales & Book Value Annual Sales$130,000.00 Price / Sales3,216.17 Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book0.63Miscellaneous Outstanding Shares254,940,000Free Float190,949,000Market Cap$418.10 million OptionableOptionable Beta-0.52 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Richard D. Klausner M.D. (Age 72)Founder & Executive Chairman Comp: $80kDr. Lynn Seely M.D. (Age 65)Ph.D., President, CEO & Director Comp: $962.23kMr. Charles W. Newton (Age 53)Chief Financial Officer Comp: $744.74kMr. Stephen J. Hill (Age 54)Chief Operating Officer Comp: $775.97kDr. Gary Lee Ph.D. (Age 47)Chief Scientific Officer Comp: $889.68kMr. Matthew Lang J.D. (Age 48)Chief Business Officer, Chief Legal Officer & Corporate Secretary Comp: $596.25kProf. Stanley R. Riddell M.D.Founder & Scientific AdvisorDr. Crystal L. Mackall M.D. (Age 63)Founder & Scientific Advisor Nellie DilleryDirector of AccountingMs. Ellen RoseSenior Vice President of Communications & Investor RelationsMore ExecutivesKey CompetitorsADC TherapeuticsNYSE:ADCTErascaNASDAQ:ERASAlectorNASDAQ:ALECAllogene TherapeuticsNASDAQ:ALLOVerve TherapeuticsNASDAQ:VERVView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 38,487 shares on 7/26/2024Ownership: 0.264%Baillie Gifford & Co.Sold 136,159 shares on 7/25/2024Ownership: 0.204%SG Americas Securities LLCSold 35,946 shares on 7/12/2024Ownership: 0.013%Simplicity Wealth LLCSold 7,430 shares on 7/10/2024Ownership: 0.007%Opaleye Management Inc.Bought 3,355,000 shares on 5/29/2024Ownership: 1.316%View All Institutional Transactions LYEL Stock Analysis - Frequently Asked Questions How have LYEL shares performed this year? Lyell Immunopharma's stock was trading at $1.94 at the beginning of the year. Since then, LYEL shares have decreased by 15.5% and is now trading at $1.64. View the best growth stocks for 2024 here. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) released its earnings results on Monday, May, 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.04. Lyell Immunopharma had a negative net margin of 335,794.09% and a negative trailing twelve-month return on equity of 33.92%. When did Lyell Immunopharma IPO? Lyell Immunopharma (LYEL) raised $425 million in an initial public offering on Thursday, June 17th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO. Who are Lyell Immunopharma's major shareholders? Lyell Immunopharma's top institutional shareholders include Bank of New York Mellon Corp (0.26%), Baillie Gifford & Co. (0.20%), SG Americas Securities LLC (0.01%) and Simplicity Wealth LLC (0.01%). View institutional ownership trends. How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LYEL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
